Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

By J. Hamanishi, M. Mandai, Takafumi Ikeda, M. Minami, A. Kawaguchi, T. Murayama, M. Kanai, Y. Mori, S. Matsumoto, S. Chikuma and 11 more. Journal of Clinical Oncology, 2015

1,042 citations recorded by the source corpus.

Subfields: Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/ef8bd64a011c0365043a0f5b78c6082121ffc834

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N. Colombo
2. J. Ledermann
3. U. Matulonis
4. A. Oaknin
5. I. Vergote
6. Jalid Sehouli
7. R. Shapira-Frommer
8. A. Lisyanskaya

Citations in the corpus

• Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. (2019, background): “Other trials have also identified clear cell histology as potentially being more responsive to checkpoint blockade [10, 19].”